Optimizing Stage 2 T1DM Management: Assessing the Impact of GLP-1Ra on Metabolic Outcomes in Patients Receiving Teplizumab
The goal of this study is to determine how a drug class called glucagon-like peptide-1 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes undergoing clinical teplizumab treatment. This study involves giving participants a liquid meal under different conditions and observing how their bodies respond, focusing on blood sugar levels, insulin effectiveness, and blood vessel function. The meal tests are followed by two post-treatment tests, one with the GLP-1Ra drug and the other with a placebo. Each test involves blood draws before and during the meal test, GLP-1Ra or placebo administration, and an ultrasound to measure blood vessel function. The goal is to see if GLP-1Ra can help manage blood sugar levels and improve cardiovascular health in this population.
• Age: 12-50 years
• BMI: 18-31 kg/m2 (adults) or 5-95th %ile (pediatric)
• Stage 2 T1DM (i.e., ≥ 2 islet auto-antibodies and:
• fasting glucose ≥ 100 mg/dL and \< 126 mg/dL OR
• 2-hr OGTT /MMTT ≥ 140 mg/dL and \< 200 mg/dL OR
• During an OGTT having a glucose of \> 199 mg/dL at 30, 60, or 90 minutes)